In another mice model bearing BRCA1-deficient ovarian tumors, anti-PD1 monotherapy exhibited a non-significant effect and PARPi monotherapy delayed tumor progression compared to control group, whereas combination therapy significantly slowed the tumor growth and prolonged survival time [147]. This evidence concerns the gene BRCA1 and neoplasm.